Popular Articles

Lutonix, Inc. Announces First Patient Enrollments In Three Separate Clinical Trials
Lutonix, Inc., a privately held medical device start-up, announced that patient enrollment is underway for its three simultaneous first-in-human clinical trials. The three studies are designed to test whether the proprietary Lutonix Drug Coated Balloon (DCB) Catheter is safe and effective in the treatment of vascular narrowing.
generic viagra online
Gilead Sciences, Tibotec To Develop Second Once-Daily HIV Treatment
Foster City, Calif.-based Gilead Sciences on Thursday said it has entered into a license and collaboration agreement with Johnson and Johnson subsidiary Tibotec Pharmaceuticals for the development and commercialization of a new once-daily fixed-dose treatment for HIV, the San Francisco Business Times reports. The FDA approved the first once-daily HIV treatment Atripla in 2006 (7/16). The new antiretroviral drug would contain Tibotec"s experimental non-nucleoside reverse transcriptase inhibitor, known as TMC278, and Gilead"s combination pill, Truvada. Kevin Young, head of commercial operations at Gilead "said the new combination pill, along with Gilead"s experimental "quad" pill, will be used for newly-diagnosed patients, with physicians reluctant to change therapy for patients who are responding well to Atripla," Reuters reports. Young said the drug is expected to reach the market in 2011 (Beasley, 7/16).
News of the day
New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate And Treatment Failure In Patients With Chronic ITP
Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The study results show Nplate significantly reduced the incidences of splenectomy and treatment failures in non-splenectomised adult patients with chronic ITP when compared to medical SOC. The results were presented today as an oral presentation at the 14th congress of the European Hematology Association (EHA abstract #1672).
Health Insurance

Language Skills In Your Twenties May Predict Risk Of Dementia Decades Later

People who have superior language skills early in life may be less likely to develop Alzheimer"s disease decades later, despite having the hallmark signs of the disease, according to research published in the July 9, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology. "A puzzling feature of Alzheimer"s disease is how it affects people differently," said study author Juan C. Troncoso, MD, with Johns Hopkins University in Baltimore. "One person who has severe plaques and tangles, the telling signs of Alzheimer"s disease in their brains, may show no symptoms affecting their memory. Another person with those same types of plaques and tangles in the same areas of the brain might end up with a full-blown case of Alzheimer"s disease. We looked at how language ability might affect the onset of symptoms." Researchers examined the brains of 38 Catholic nuns after death. The participants were part of the Nun Study, an ongoing clinical study of Catholic sisters of the School Sisters of Notre Dame congregation living in the United States. Scientists determined two groups: women with memory problems and Alzheimer"s disease hallmarks in the brain and women with normal memory with or without signs of Alzheimer"s disease in the brain. The researchers analyzed essays that 14 participants wrote as they entered the convent in their late teens or early 20"s. They studied the average number of ideas expressed for every 10 words. The analysis also measured how complex the grammar was in each essay. The study found that language scores were 20 percent higher in the women without memory problems compared to those with memory problems. The grammar score, however, did not show any difference between the two groups. "Despite the small number of participants in this portion of the study, the finding is a fascinating one," Troncoso said. "Our results show that an intellectual ability test in the early 20s may predict the likelihood of remaining cognitively normal five or six decades later, even in the presence of a large amount of Alzheimer"s disease pathology." The study also measured how growth in brain cells might be part of the brain cell"s early response to Alzheimer"s disease or how these cells may prevent memory impairment despite a large amount of Alzheimer"s disease lesions. The study found significant increases in the size of brain cells in nuns with normal thinking skills and Alzheimer"s disease hallmarks compared to people with memory problems and those with normal thinking skills and without the signs of Alzheimer"s disease. "Perhaps mental abilities at age 20 are indicative of a brain that will be better able to cope with diseases later in life," said Troncoso. The study was supported by the Johns Hopkins University Alzheimer"s Disease Research Center, the National Institutes of Health, the Nun Study, the National Institute on Aging, the University of Kentucky Alzheimer"s Disease Center, the Abercrombie Foundation and the Kleberg Foundation. The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as epilepsy, dystonia, migraine, Huntington"s disease, and dementia. American Academy of Neurology (AAN)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):